In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Immunotherapy biomarkers

Original research

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies

Online download statistics by month:

Online download statistics by month: March 2022 to March 2024

	Abstract	Full	Pdf
Mar 2022	894	917	458
Apr 2022	393	417	190
May 2022	312	340	182
Jun 2022	477	498	181
Jul 2022	450	467	163
Aug 2022	547	558	138
Sep 2022	484	514	200
Oct 2022	464	479	179
Nov 2022	351	353	127
Dec 2022	230	233	95
Jan 2023	202	204	74
Feb 2023	253	260	111
Mar 2023	277	278	164
Apr 2023	243	249	118
May 2023	216	218	88
Jun 2023	176	182	81
Jul 2023	205	209	92
Aug 2023	218	222	119
Sep 2023	194	197	75
Oct 2023	167	167	73
Nov 2023	247	248	96
Dec 2023	246	247	165
Jan 2024	180	181	137
Feb 2024	249	249	94
Mar 2024	629	633	269
Total	8304	8520	3669